tbuckley/cabot-search huggingface dataset:
PTH-144 Anaemia of Chronic Disease: High Malignancy Yield
Authors: J Schembri, MS Lau, J Hebden
Journal: Gut (2016)

<h3>Introduction</h3> Anaemia of chronic disease (ACD) is said to be associated with prolonged inflammation or infection, or malignancy. We sought to determine the yield of investigations in a cohort of patients referred to the outpatient clinic with blood tests compatible with ACD. <h3>Methods</h3> We prospectively collected data on patients attending a single consultant led iron-deficiency anaemia (IDA) clinic, who did not fulfil the criteria for iron deficiency anaemia, from 2013–2015. These patients were investigated according to symptoms and blood tests by a single consultant physician. <h3>Results</h3> A total of 371 patients were referred with the label of IDA. Iron deficiency anaemia was confirmed in 282 patients, and isolated iron deficiency in a further 11 patients, leaving 78 (21%) who did not fulfil the criteria and were deemed to have ACD (age range 45–92; 53 males). Thirty two (41%) were asymptomatic. Malignancy was discovered in 11 (14%) (colorectal 2, lung 2, prostate 2, combined gastric and colonic 1, gastric 1, renal 1, cervical 1, lymphoma 1). Three of the 11 patients with malignancy were asymptomatic (2 lung, 1 colonic). The majority (9/11) were evident on CT scanning of the chest, abdomen and pelvis. Other diagnoses responsible for ACD (23) were: chronic kidney disease (CKD) 7, haemoglobinopathy 3 (with associated CKD in 1), MGUS 3, myelodysplastic syndrome 2, low B12 2 (metformin in 1), haematoma 1, haemorrhagic gastritis 1, menorrhagia 1, pernicious anaemia 1, polymyalgia rheumatica 1, seronegative coeliac disease 1. No cause for the anaemia was found in 43 (56%) of the cohort. <h3>Conclusion</h3> The prevalence of malignancy in ACD is high. Cross-sectional imaging as a first line investigation will pick up the majority of malignancies. CKD is a common cause of ACD. No cause of ACD is found in over half of patients. <h3>Disclosure of Interest</h3> None Declared
SAT0585 Barriers To T2T Implementation: RA Patient's Perspectives about Comorbidities and Structural Damage in Therapeutic Decisions
Authors: I. Laurindo, L. Mota, L. Romeiro, R. Ranza, M. Freitas, I. Pereira, J. Vasconcelos, C. Brenol, L. Rezende, M. Bertolo, D. Torigoe
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> T2T strategies have been largely recognized and incorporated in national guidelines. Structural changes, functional impairment and comorbidities should be considered along with RA disease activity state when making therapeutic decisions. <h3>Objectives</h3> To evaluate patient9s perspectives on the interference of comorbidities and structural changes/functional impairment in treatment decisions. <h3>Methods</h3> RA patients (1987 criteria) in regular follow-up were recruited from community (private practice) and academic public medical centers by 11 investigators in different urban and rural areas of the country. Structured questionnaires were applied and socio-demographics, disease activity and treatment data were collected. The focus of this study was two main questions: a) In your opinion, other diseases that you have can change the arthritis treatment? b) Do you think that having deformities modify your treatment? Affirmative answers would be followed by more specific questions. Statistical analysis: ANOVA or Kruskal-Wallis; Fisher or Fisher-Freeman-Halton (FFH) as needed; p&lt;0.05. Data expressed as % [95%CI} or mean (SD). <h3>Results</h3> 485 RA patients were included, 89.7% females, mean age 52.3 (13.8) years, 8.0 (5.2) years of education; 32.4% in use of biologics and 28.3% in private practice. Less than 40% of the patients considered that any of these conditions influenced the treatment. Deformities, surrogate for structural damage, were considered to imply in more severe disease or more pain and medications by respectively 54.8% and 34% of the positive responders (n=177); these patients were more frequently living in the northwest area (60.2vs 31.7%; =0.0001; [16.2–40]), were from higher socio-economic level (43.2vs30.2%; p=0.0001; [4,1–21.7]), younger (49.4 (12.3) vs 54.3 (12,7); p&lt;0,001) and with shorter disease duration (median 8.0 (range4.0–15) vs 12 (6.0–19); p&lt;0.001). Regarding comorbidities, there were 39.4% (n=191) positive answers, predominantly from younger patients [51.3 (13.1) vs 54.5 (11.6); p&lt;0.003]. The patients from private system (80.3 vs 56.3%;p=0.0004; [9.3–36.7]) and higher socio-economic level (71.8 vs55%; p=0.01;[2.9–30.1]), as well as patients with more schooling years (p&lt;0.001) and shorter disease duration (p&lt;0.041) worried that comorbidities could hinder the choice of arthritis medication, while some patients from public service (25.5vs9.8%;p=0,01;[3.2–25.8]) and low socio-economic levels (14 vs 1.99%;p=0,001;[4.1–20.6]) had concerns about too many pills. <h3>Conclusions</h3> patient9s skepticism about comorbidities or structural changes interfering with their therapeutic decisions is prevalent and needs to be addressed. <h3>Disclosure of Interest</h3> None declared
Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,
Authors: Catherine C. Smith, Michael Brown, Jason Chin, Corynn Kasap, Sara Salerno, Lauren E. Damon, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, Neil Shah
Journal: Blood (2011)
SAT0117 Quality Assessment in The Management of Patients with Rheumatoid Arthritis. Implementation of The “Treat To Target” Strategy
Authors: J.L. Andreu, M.A. Martín, J.J. Pérez-Venegas, J.-A. Román-Ivorra, H. Corominas, A. Gil, F. Sánchez-Alonso, T. Jiménez, M.A. Sánchez Ruiz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The current paradigm of optimal clinical management of patients with rheumatoid arthritis (RA) recommends reaching a state of remission or low activity of the disease, assessed by composite indexes of activity, by means of a tight control and a dynamic adjustment of available therapeutic options, using a “treat to target” strategy. <h3>Objectives</h3> The aim of this study is to assess the level of implementation of the “treat to target” strategy and other parameters of medical quality in clinical records (CRs) of RA patients in Spanish rheumatology departments. <h3>Methods</h3> Adult RA patients fulfilling 2010 ACR-EULAR criteria for RA and diagnosed between January 1st, 2010 and December 31st, 2013 in Spanish rheumatology departments were included. From every centre, 19 patients were randomly chosen from a computerized anonymized list provided by every department. Independent auditors assessed the CRs, verifying the fulfilling of the quality criteria included in an assessment tool specifically developed for this project. The study was approved by the ethic committees of every participant hospital. Descriptive statistics was used for the presentation of the results. <h3>Results</h3> A total of 856 CRs from 46 rheumatology departments were included. Patients9 mean age was 54 years and 71% of patients were women. Mean duration of RA was 2 years. During the follow-up, 38% of patients reached a state of low disease activity, defined by DAS28 and/or SDAI. An explicit assessment of the disease activity as a determinant element considered to choose the therapy was recorded in 32% of the CRs. An optimal escalation of methotrexate dose was registered in 72% of the cases. Use of a composite disease activity score (DAS28, SDAI, CDAI) was reported in 61% of the cases. Disease activity monitoring every 6–8 months after reaching the therapeutic target was recorded in 73% of the cases. In 99% of the cases, the clinicians had registered patient9s comorbidities and these associated conditions had been considered in planning the therapeutic approach and objective. In only 4% of the CRs, visits every 4 weeks using a composite activity score had been reported during the early stage while trying to reach remission after diagnosis. Starting a DMARD in the first two weeks after the first appointment with the rheumatologist was recorded in only 35% of the cases. <h3>Conclusions</h3> Currently, the implementation of the “treat to target” strategy is scarcely registered in clinical records of patients diagnosed with RA in Spanish rheumatology departments. A minority of patients is treated according to the “Treat to target” recommendations. <h3>Disclosure of Interest</h3> None declared
Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib
Authors: Melissa G. Ooi, Patrick J. Hayden, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Noopur S Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C Anderson, Nicholas Mitsiades
Journal: Blood (2008)
Minimal Residual Disease After Allogeneic Stem Cell Transplantation: A Comparison Among Multiparameter Flow Cytometry, Wilms Tumor 1 Expression and Chimerism Status (Complete vs Low-Level Mixed Chimerism) in Patients with Acute Leukemia
Authors: Giovanni Rossi, Angelo Michele Carella, Maria Marta Minervini, Lucia Savino, Andrea Fontana, Fabio Pellegrini, Michele Mario Greco, Emanuela Merla, Giovanni Quarta, Giacomo Loseto, Silvana Capalbo, Gaetano Palumbo, Nicola Cascavilla
Journal: Blood (2012)
Cancer risk among 21st century blood transfusion recipients
Authors: T.O. Yang, B.J. Cairns, G.K. Reeves, J. Green, V. Beral
Journal: Annals of Oncology (2016)

BackgroundSome carcinogenic viruses are known to be transmissible by blood transfusion. Intensive viral screening of transfused blood now exists in most countries. In the UK, high-sensitivity nucleic acid amplification tests for hepatitis C virus were introduced in 1999 and it was thought that this would reduce, and possibly eliminate, transfusion-related liver cancer. We aimed to investigate cancer risk in recipients of blood transfusion in 2000 or after.MethodsA total of 1.3 million UK women recruited in 1998 on average were followed for hospital records of blood transfusion and for cancer registrations. After excluding women with cancer or precancerous conditions before or at the time of transfusion, Cox regression yielded adjusted relative risks of 11 site-specific cancers for women with compared to without prior blood transfusion.ResultsDuring follow up, 11 274 (0.9%) women had a first recorded transfusion in 2000 or after, and 1648 (14.6%) of them were subsequently diagnosed with cancer, a mean 6.8 years after the transfusion. In the first 5 years after transfusion there were significant excesses for most site-specific cancers examined, presumably because some had preclinical cancer. However, 5 or more years (mean 8 years) after blood transfusion, there were significant excess risks only for liver cancer (adjusted relative risk = 2.63, 95%CI 1.45–4.78) and for non-Hodgkin lymphoma (adjusted relative risk = 1.74, 1.21–2.51). When analyses were restricted to those undergoing hip or knee replacement surgery, the commonest procedure associated with transfusion, these relative risks were not materially altered.ConclusionsIn a large cohort of UK women, transfusions in the 21st century were associated with long-term increased risks of liver cancer and non-Hodgkin lymphoma. Some of these malignancies may have been caused by carcinogenic agents that are not currently screened for in transfused blood.
PTU-083 Long-Term Follow-Up of Patients with Autoimmune Hepatitis after Withdrawal of Immunosuppressant Therapy
Authors: L Harrison, J Adams-Nye, E Lawrence, E McFarlane, B Hoeroldt, D Gleeson
Journal: Gut (2016)

<h3>Introduction</h3> If immunosuppressant therapy (IST) is withdrawn in patients with autoimmune hepatitis (AIH) when remission is achieved, 50–70% will have a disease relapse within 12 months. Thus, many patients receive long-term maintenance IST. However, IST has potential side effects, including an increased cancer risk. Recent studies suggest a lower AIH relapse rate if IST is withdrawn at a later stage in the disease. Data are lacking in regard to long-term outcome following IST withdrawal. <h3>Methods</h3> Retrospective audit of long-term outcome of AIH following withdrawal of IST. A total of 282 patients with definite or probable AIH by International AIH Group criteria, had presented to our Unit between 1971–2015 and had achieved normalisation of serum ALT within 12 months of starting IST (prednisolone plus azathioprine, or mycophenolate if azathioprine intolerant). From these, we found 25 patients in whom all IST was subsequently discontinued. We assessed outcome in these patients, in comparison to those who continued IST. Follow-up was until last serum ALT for calculating relapse rate and until death or last known to be alive for calculating survival rates. <h3>Results</h3> The 25 patients (21 female, age at diagnosis 50 (8–68) years) had been on IST before withdrawal for 3.9 (0.1–22.4) years. Five had cirrhosis at presentation. All patients had normal serum ALT and globulins at time of withdrawal except one patient with acute pancreatitis. Reasons for IS withdrawal were: cancer (6), infections (3), side effects (4), frailty (6) patient choice (6), doubt about diagnosis (subsequently resolved) (1). Relapses occurred in 7 patients (28%) after 1.6 (0.5–9.6) years. Relapse rates were 15%, 20% and 28% after 2, 5 and 10 years respectively. All patients achieved re-normalisation of serum ALT within 3 months of re-starting therapy (prednisolone 10–40 mg/day) plus (in 5 patients) azathioprine or mycophenolate, subsequently continued as maintenance therapy. Over follow up (from IST withdrawal) of 4.2 (1.2–25.1 years), no patient developed liver decompensation, variceal bleeding or hepatocellular carcinoma. Six patients died after 4 (3.3–15.9) years; none due to liver disease or following AIH relapse. Patients stopping IST (n = 25) had, compared to those who continued IST (n = 257) higher 10- and 20 year survival (99±4% and 79±9% respectively vs 78±3% and 48±4% p = 0.021). <h3>Conclusion</h3> In patients with AIH who achieve remission a trial of withdrawal of IS therapy is associated with (a) a lower disease relapse rate than previously reported, (b) no liver adverse events and (c) no reduction in long-term survival compared with patients who continue on long-term IS therapy. <h3>Disclosure of Interest</h3> None Declared
Chronic Myeloid Leukemia. 15-Years Experience at a Single Institution in Mexico City.
Authors: Alvaro Aguayo, Eunice Garcia-Alvarez, Yael Cazares-Ordonez, Erick Crespo-Solis, Deborah Martinez-Banos, Guadarrama-Beltran S.W. Elizabeth, Eduardo E. Cervera-Ceballos, Xavier Lopez-Karpovitch
Journal: Blood (2007)
Utilization of Peripheral Blood Cell-Free DNA in Myelodysplastic Syndromes: Clinical and Molecular Characteristics and Utilization for Genetic Analyses Using Conventional and Next-Generation Strategies
Authors: Akihiro Tomita, Yasuhiro Suzuki, Fumika Nakamura, Chisako Iriyama, Mizuho Shirahata-Adachi, Kazuyuki Shimada, Akimi Akashi, Yuichi Ishikawa, Norio Kaneda, Hitoshi Kiyoi
Journal: Blood (2015)
A Multicenter Randomized Trial Comparing Response-Adapted (RA), Non-Cross-Resistant Induction and Consolidation with Idarubicin/Cytarabine (IDAC) Followed by Mitoxantrone/Etoposide (NOVE) Compared with Consolidation with High Dose Cytarabine (HDAC) in Adult Patients with AML. A Study by the Canadian Leukemia Studies Group (CLSG).
Authors: Richard H.C. van der Jagt, K. S. Robinson2, D. P. Sheridan3, R. Delage4, L. M. Larratt5, E. Yetisir6, G. A. Wells7
Journal: Blood (2005)
Analysis of Procoagulants Phospholipids in Plasma of Paroxysmal Nocturnal Hemoglobinuria Patients,Processed in Differents Preanalytic Conditions
Authors: Cristina Muñoz, Jose A Garcia-Marco, Santiago Gil, Emilio Ojeda, Rafael Fores, Guiomar Bautista, Isabel Krsnik, Belen Navarro, Almudena de LaIglesia, Isabel San Juan, Carmen Regidor, Isabel Millan, Jose Rafael Cabrera, Miguel Piris, Mirian Santero, Nuria Claros, Pilar Beltran, Martin Cabero, Daniel Morillo, Trinidad Martin, Rosa Gonzalo, Beatriz Azcoitia
Journal: Blood (2011)
Trial of novel leukaemia drug is stopped for second time after two more deaths
Authors: Nigel Hawkes
Journal: BMJ (2016)

A trial that had already been stopped and restarted in July, after three participants died,1 2 has been suspended once again after two more patients died.

Juno Therapeutics of Seattle, Washington, stopped its phase II trial into an immunological treatment for acute lymphocytic leukaemia on 23 November after two patients died. They had symptoms identical to those of the first three patients who died: brain swelling caused by excess fluids (cerebral oedema).

Although patients enlisted in the trial all had a lethal disease and few options left, questions are likely to be asked …
Successful Translation of a GMP-Based, Clinical Scale Selective Allodepletion Approach for Matched Donor-Recipient Pairs from Bench-to-Bedside.
Authors: Stephan Mielke, Raquel Nunes, Katayoun Rezvani, Vicki S. Fellowes, Annie Venne, Scott R. Solomon, Yong Fan, Christian Scotto, Elizabeth J. Read, A. John Barrett
Journal: Blood (2007)
Evaluation of Residual Platelet Reactivity in Patients Treated with Aspirin and or Clopidogrel: Comparison of Results Obtained On Multiplate®, PFA-100TM and Classical Light Transmission Aggregometry.
Authors: Annick Ankri, Isabelle Martin-Toutain, Anne Baranger, Marie-Claude Couty, Jean Philippe Collet, Gilles Montalescot
Journal: Blood (2009)
FRI0111 Dental Association or Incidental Finding? A Meta-Analysis and Systematic Review of The Relationship between Rheumatoid Arthritis and Periodontitis
Authors: N.R. Fuggle, T.O. Smith, A. Kaul, N. Sofat
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) and periodontitis are both chronic inflammatory diseases sharing potential mechanisms including histopathology and demography. An association between these conditions has been demonstrated previously but published studies have not been subjected to meta-analysis with respect to large populations worldwide to fully unravel associations across distinct ethnicities. <h3>Objectives</h3> The aim of this analysis was to interogate the relationship between rheumatoid arthritis and periodontitis in the context of the earliest to the most recent literature. <h3>Methods</h3> The published databases MEDLINE, EMBASE and PsycINFO were searched using search terms related to RA and periodontitis. Articles were selected if they included data on the number of people with RA diagnosed with periodontitis (or periodontal disease parameters) compared to a control comparison group. Review articles, case reports, animal model studies, non-English language and articles with unavailable abstracts were excluded. Data was extracted, critically appraised using the Downs and Black appraisal tool and a fixed-effect Mantel-Haenszel meta-analysis was performed. <h3>Results</h3> A total of 21 papers met the eligibility criteria and provided data for the meta-analysis; 17 studies (including a total of 153,492 participants) comparing RA to healthy controls and 4 (including a total of 1378 participants) comparing RA to osteoarthritis (OA) were evaluated. Studies included patients populations from diverse geographical locations including Taiwan, Japan, India, Holland and the United States. There was a significantly increased risk of periodontitis in people with RA compared to healthy controls (RR: 1.13; 95% CI: 1.04, 1.23; p=0.006; N: 153,277) with a significantly raised mean probing depth, risk of bleeding on probing (BOP) and absolute value of clinical attachment loss in those with rheumatoid arthritis (Figure 1). When comparing RA and OA, there was no significant difference in the prevalence of periodontitis, however the risk of BOP was greater in OA than RA. <h3>Conclusions</h3> The very strong association between RA and periodontitis is supported by the results of our systematic review and meta-analysis of studies comparing RA to healthy controls Our data show that the association of RA and periodontitis is a significant observation seen worldwide across a range of ethnicities, suggesting common shared mechanisms in both conditions. Future work is required to unravel the basic molecular pathways underlying RA and periodontitis. <h3>Disclosure of Interest</h3> None declared
The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bclxl) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy
Authors: Melisa Martinez-Paniagua, Mario I. Vega, Sara Huerta-Yepez, Hari Hariharan, Haiming Chen, James R. Berenson, Benjamin Bonavida
Journal: Blood (2010)
Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.
Authors: Frederic Baron, R. Storb, B. Storer, D. Maloney, M. Maris, D. Niederwieser, J. Shizuru, T. Chauncey, B. Bruno, S. Forman, P. McSweeney, R. Maziarz, M. Pulsipher, E. Agura, M. Sorror, J. Wade, B. Sandmaier
Journal: Blood (2005)
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
Authors: Bo Cai, Mei Guo, Yao Wang, Yajing Zhang, Jun Yang, Yelei Guo, Hanren Dai, Changlin Yu, Qiyun Sun, Jianhui Qiao, Kaixun Hu, Hongli Zuo, Zheng Dong, Zechuan Zhang, Mingxing Feng, Bingxia Li, Yujing Sun, Tieqiang Liu, Zhiqing Liu, Yi Wang, Yajing Huang, Bo Yao, Weidong Han, Huisheng Ai
Journal: Journal of Hematology & Oncology (2016)

Elderly patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have poor prognosis. Autologous CD19 chimeric antigen receptor-modified T (CAR-T) cells have potentials to cure patients with B cell ALL; however, safety and efficacy of allogeneic CD19 CAR-T cells are still undetermined. We treated a 71-year-old female with relapsed and refractory ALL who received co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC) following induction chemotherapy. Undetectable minimal residual disease by flow cytometry was achieved, and full donor cell engraftment was established. The transient release of cytokines and mild fever were detected. Significantly elevated serum lactate dehydrogenase, alanine transaminase, bilirubin and glutamic-oxalacetic transaminase were observed from days 14 to 18, all of which were reversible after immunosuppressive therapy. Our preliminary results suggest that co-infusion of haplo-identical donor-derived CAR-T cells and mobilized PBSCs may induce full donor engraftment in relapsed and refractory ALL including elderly patients, but complications related to donor cell infusions should still be cautioned. Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL. NCT02799550
Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with Beta-Thalassemia Major
Authors: M Akif Yesilipek, Gulsun Karasu, Zuhre Kaya, Baris B Kuskonmaz, Vedat Uygun, Ilkiz Dag, Asli Birkent, Mehmet Ertem
Journal: Blood (2015)
Gene Expression Profile Reveals a Unique Pattern of Protein Kinases in Chronic Lymphocytic Leukemia (CLL): Potential Role of the Second Generation Protein Kinase Inhibitors.
Authors: Simona Tavolaro, Sabina Chiaretti, Monica Messina, Nadia Peragine, Roberta Maggio, Ilaria Del Giudice, Emanuela M. Ghia, Francesca R. Mauro, Anna Guarini, Robert Foa
Journal: Blood (2007)